Oral antiarrhythmic agents for ventricular arrhythmias

Area of Science:

• Cardiology
• Electrophysiology

Background:

• Ventricular tachyarrhythmia is a primary cause of sudden cardiac death.
• Current risk stratification involves Holter monitoring and assessing left ventricular function.
• The efficacy of preventing sudden cardiac death in patients with lethal ventricular arrhythmias remains uncertain.

Purpose of the Study:

• To review the current landscape of antiarrhythmic drug therapy for ventricular arrhythmias.
• To discuss the role of new oral antiarrhythmic agents.
• To highlight the Vaughan-Williams classification in guiding treatment decisions.

Main Methods:

• Review of antiarrhythmic drug classes based on the modified Vaughan-Williams classification.
• Discussion of clinical applications for Class IC, Class II (beta-blockers), and Class III (amiodarone) agents.
• Analysis of treatment strategies for benign and potentially lethal ventricular arrhythmias.

Main Results:

• Class IC antiarrhythmic agents are emerging as first-choice treatments for various ventricular arrhythmias.
• Beta-blockers are indicated for arrhythmias associated with myocardial ischemia or post-myocardial infarction.
• Amiodarone is reserved for severe, life-threatening arrhythmias refractory to other treatments due to potential side effects.

Conclusions:

• The choice of antiarrhythmic therapy depends on the specific arrhythmia and patient characteristics.
• Class IC agents show promise for broad application in ventricular arrhythmia management.
• Further research is needed to confirm the ability of these agents to prevent sudden cardiac death.